Monday Pre-Market Insights: MU, GERN, PTBI
TipRanks | Jun 15, 2015 08:34AM ET
Micron Technology (NASDAQ:GERN ) increased 6.17% to $4.30 in pre-market trading on Monday after Oppenheimer analyst Ling Wang issued an Outperform rating on the stock. Furthermore, the FDA granted orphan drug status to imetelstat, a therapy for myelofibrosis; a rare form of bone marrow cancer. According to TipRanks, two analysts have open positions on Geron (NASDAQ:GERN), both of which are Buy ratings. The average 12-month price target on the stock is $5.75, marking a 42% potential upside based on where the stock is currently trading.
PlasmaTech Biopharmaceuticals Inc (NASDAQ:PTBI ) shares increased 3.82% in pre-market trading to $7.61 after the pharmaceutical company announced that it has added another AAV gene therapy to its pipeline. The therapy was licensed from the University of Minnesota and aims to treat Fanconi anemia and other rare blood diseases. According to TipRanks, two analysts currently have open positions on PlasmaTech Biopharmaceuticals (NASDAQ:PTBI), both of which are Buy ratings. The average 12-month price target on the stock is $15.50, marking a 111% potential upside from where the stock is currently trading.
Bluebird bio Inc (NASDAQ:BLUE ) shot up 5.8% in pre-market trading to $191.31 after the biopharmaceutical company announced new data from HGB-205, a study that tested LentiGlobin BB305. The experimental therapy aims to treat beta thalassemia, a rare blood disorder. On June 13 Bluebird bio Inc (NASDAQ:BLUE) announced that the therapy enabled a patient with severe Sickle Cell Disease to go three months without receiving a blood transfusion. According to the seven analysts polled by TipRanks, all seven of them recommend Buying BLUE. Out of the seven analysts, the average 12-month price target for the stock is $203.67, marking a 12.6% potential upside from where the stock is currently trading.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.